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Abstract
Rationale Adversedrugeffectssuchasreducedalertnessmay
cause drivers to be unaware that their driving is impaired.
Objective This study was conducted to examine if drivers
are adequately aware of their driving ability when treated
with central nervous system drugs.
Methods Data from three clinical trials applying the on-the-
road driving test were used to compare the primary
outcome measure, the Standard Deviation of Lateral
Position, with subjective assessments of alertness before
driving, as well as perceived driving quality, and mental
effort to perform the test.
Results The analyses revealed significant correlations for
perceived driving quality (r=−0.498, p<0.0001), mental
effort to perform the test (r=0.408, p<0.0001), and
alertness taken before driving (r=−0.115, p<0.017). The
predictive validity (R
2) of perceived driving quality
(24.8%), mental effort (16.6%), and alertness before driving
(1.3%) was low.
Conclusion The analyses show that subjective assessments
do not robustly relate to actual driving performance either
in terms of judgments about alertness before the drive or
ratings of performance after the drive.
Keywords Driving.SDLP.Subjective assessments.
Alertness.Effort
Introduction
Drivers who experience reduced alertness or other adverse
effects of central nervous system (CNS) drugs often show
impaired driving. Being aware of adverse CNS drug effects
and recognizing that driving is impaired are essential for
making appropriate countermeasures. If individuals are
aware of adverse drug effects, they may choose not to
drive. Alternatively, if they acknowledge that their driving
is impaired, they can stop driving before an accident occurs
or can drive shorter periods of time, or avoid taking the
drug on future occasions when they plan to drive.
Unfortunately, research has shown that drivers can poorly
judge their own driving performance.
Drivers often overestimate their skills and abilities and
do not recognize impairment. For example, it has been
shown that 70–90% of drivers feel their driving is better
and less risky than that of the average driver (Svenson
1978, 1981; McCormick et al. 1986; Groeger and Brown
1989; Sivak et al. 1989). Men and women do not differ in
overestimating their own driving ability (McCormick et al.
1986; Groeger and Brown 1989). Subjective ratings of
driving ability were shown to differ between countries and
cultures and may depend on factors such as driving
experience, age, personality, and crash experience
(Matthews and Moran 1986; Sivak et al. 1989; Holland
1993; Lajunen and Summala 1995; Lajunen et al. 1998).
Although there is a bias towards a more positive view of
drivers’ own skills and abilities, this does not necessarily
mean that they are unable to adequately assess changes in
their driving performance, for example those induced by
CNS drugs and alcohol. Research that tested drivers who
were unfit for driving due to medical conditions such as
stroke showed that patients who fail a driving test often have
limited awareness of their disability and corresponding
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DOI 10.1007/s00213-011-2400-7negative consequences with regard to driving (Patomella et
al. 2008). Of 152 elderly drivers tested in a driving simulator,
65% rated their performance better than the average driver
(Freund et al. 2005). However, about half of them showed
unsafe driving performance on the simulator test.
Previous research that compared subjective driving
quality and actual driving performance suffers from
methodological issues. The measurement of actual driving
performance was typically accomplished by means of
psychometric tests in the laboratory, driving simulators, or
closed-road driving tests. It can be questioned to what
extent these tests represent and predict actual driving and
the degree to which subjects think this relates to real
driving. The primary reason for this is that in these tests
there is no risk to the driver, which will cause participants
to behave differently than in actual traffic. Other studies did
use on-road assessments, but performance was rated by the
experimenter or a driving instructor, not the driver. Finally,
measurement tools are not standardized across studies
which make comparing the results difficult.
This paper examines the relationship between subjective
assessments and actual driving impairment, objectively
measured by the on-the-road driving test. The on-the-road
driving test in normal traffic (Verster and Roth 2011) is the
gold standard method to examine the effects of CNS drugs
on driving. The 100-km standardized test was developed in
the 1980s (O’Hanlon et al. 1982;O ’Hanlon 1984) and has
been applied in over 75 clinical trials. Participants are
instructed to drive with a steady lane position and a
constant speed. The Standard Deviation of Lateral
Position (SDLP), i.e., the “weaving” of the car, is the
primary parameter of the test. The test has proven
sensitivity to measure dose-dependent impairment of a
variety of CNS drugs, and comparative research with
alcohol, THC, and benzodiazepines showed that dose-
related changes in SDLP correlate high with the risk of
becoming involved in traffic accidents (Owens and
Ramaekers 2009).
As a standard procedure in clinical trials applying the on-
the-road driving test, subjective assessments are conducted to
determine levels of alertness before driving, and after driving
perceiveddriving quality,andmentaleffortneededtoperform
the drive. Based on the literature discussed above, it is
hypothesized that drivers are unable to accurately estimate
(changes in) their driving performance.
Methods
Data from three studies were used to compose the current
data set (Verster et al. 2002a, b, 2003, 2006). The Medical
Ethics Committee of the University Medical Center Utrecht
approved the study protocols, and subjects were treated
according to ICH guidelines for Good Clinical Practice and
the Declaration of Helsinki and its amendments.
Participants
A total of 96 healthy volunteers completed the three
studies. In each study, male and female participants were
equally represented. Mean (SD) age was 23.9 (2.2) years
old. Written informed consent was obtained before their
participation. Subjects were medically screened, used no
concomitant medication other than paracetamol and oral
contraceptives, and they had no unstable medical disorders,
history of psychiatric disease, alcohol or drug abuse. Before
the start and at the end of the studies, blood chemistry and
hematology and urinalysis were determined, and a 12-lead
ECG was recorded. All assessments were within normal
limits. To confirm drug status, at all visits subjects were
tested on the presence of alcohol and drugs of abuse
(amphetamines, barbiturates, cannabinoids, benzodiaze-
pines, cocaine, and opioids). In addition, female subjects
underwent β-HCG pregnancy tests. None of the subjects
were positive on any of these drugs. Subjects possessed a
valid driver’s license, drove more than 5,000 km/year
during each of the past 3 years, and were trained on the
driving tests. A thorough discussion on the inclusion and
exclusion criteria of participants and description of the
study designs can be found in the individual reports (Verster
et al. 2002a, b, 2003, 2006).
Treatments
A variety of treatments were tested in the three studies,
including alcohol, hypnotics, anxiolytics, analgesics, and
H1-antihistamines. The specific drugs and their dosages are
summarized in Table 1.
The on-the-road driving test
Standardized 100-km driving tests (Verster and Roth, 2011)
were performed on a primary highway during normal
traffic, between the cities of Utrecht and Arnhem. A
camera, mounted on the roof of the test vehicle, measured
the vehicle’s lateral position relative to the road delineation.
Participants were instructed to drive with a steady lateral
position within the right traffic lane while maintaining a
constant speed of 95 km/h (60 mph). The amount of
“weaving” of the car, measured by the standard deviation of
the lateral position (SDLP, centimeters), was the primary
outcome parameter. The standard deviation of speed (kilo-
meters per hour) was a secondary parameter. Duration of
the driving test was approximately 75 min.
Patients were allowed to deviate from the instructions to
overtake a slower-moving vehicle in the same traffic lane.
776 Psychopharmacology (2012) 219:775–781The vehicle’s speed and lateral position were continuously
recorded. A licensed driving instructor who had access to
dual controls sat in the right front seat, guarding the
subject’s safety. Tests could be terminated if the driving
instructor or the subject felt it was unsafe to continue.
Before disclosure of treatment blinding, the data were
edited off-line to remove data that were disturbed by
extraneous events (e.g., overtaking maneuvers and traffic
jam), and SDLP values were calculated.
Subjective assessments
Before the driving test, subjective alertness was measured
using a 21-point visual analog scale. After the driving test,
subject estimates of their driving quality and mental effort to
performitweremeasured.Participantsindicatedtheperceived
quality of their driving performance on a visual analog scale,
which ranged from 0 (“I drove exceptionally poorly”)t o2 0
(“I drove exceptionally well”) around a midpoint of “Id r o v e
normally.” The level of mental effort they had to exert to
perform the task was indicated on a 15-cm interval scale,
ranging from “absolutely no effort” to “extreme effort”
(Zijlstra and Van Doorn 1985; Meijman et al. 1986).
Statistical analysis
For each treatment, difference scores from placebo were
calculated for each dependent variable. The data of the
Reference Subjects Time after
administration (h)
Treatments
(Verster et al. 2002a) 30 1 Placebo
Alcohol (BAC 0.05%)
(Verster et al. 2002a)3 0 9 –10 Placebo
Zaleplon 10 mg
Zaleplon 20 mg
Zolpidem 10 mg
Zolpidem 20 mg
(Verster et al. 2002b;
Verster et al. 2006)
18 1 Placebo
Bromfenac 25 mg
Bromfenac 50 mg
Oxycodone/paracetamol 5/325 mg
Oxycodone/paracetamol 10/650 mg
Alprazolam 1 mg
(Verster et al. 2003) 48 1 (day 1 and day 4) Placebo
Levocetirizine 5 mg
Diphenhydramine 50 mg
Table 1 Administered drugs in
the three driving studies
BAC blood alcohol
concentration
Treatment N SDLP Mental effort Driving quality Alertness
Zolpidem (20 mg) 30 +10.41* +2.25* −4.23* −5.53*
Alprazolam (1 mg) 18 +9.62* +3.76* −5.17* +3.94*
Zolpidem (10 mg) 30 +3.35* +0.52 −1.75 −2.83*
Diphenhydramine (50 mg, day 1) 48 +2.74* +2.67* −3.66* +2.94*
Oxycodone/paracetamol (10/650 mg) 18 +1.87 +3.29* −3.83* +4.22*
Diphenhydramine (50 mg, day 4) 48 +1.56* +0.42 −0.44 +1.46*
Alcohol (BAC=0.05%) 29 +1.03* +0.07 −0.12 −3.33*
Bromfenac (50 mg) 18 +0.51 +0.59 −1.62 +0.61
Levocetirizine (5 mg, day 4) 48 +0.46 −0.04 −0.22 +0.02
Zaleplon (10 mg) 30 −0.45 −0.07 +0.59 −0.30
Zaleplon (20 mg) 30 +0.43 +0.84 −0.26 −1.30
Levocetirizine (5 mg, day 1) 48 +0.22 +0.85 −1.23 +0.06
Oxycodone/paracetamol (5/325 mg) 18 −0.65 +0.93 −1.53 +1.94*
Bromfenac (25 mg) 18 −0.66 +0.42 −1.82 +0.61
Table 2 Differences from
placebo (centimeters) for SDLP,
perceived driving quality, mental
effort to perform the test, and
alertness before driving
*p<0.05, significant differences
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comparisons between changes in the primary parameter of
the driving test (SDLP) and difference scores for the
subjective assessments (driving quality, mental effort taken
after driving, and alertness taken before driving). Pearson’s
r correlations were computed; significance was established
if p<0.05 (two-tailed). The analyses were done for all data
combined, as well as for the individual drug treatments.
Results
Data from N=604 driving tests (N=96 participants) and
corresponding subjective assessments were available for the
statistical analysis. For the difference scores from placebo, a
total of N=431 comparisons could be made. Table 2
summarizes differences from placebo and their statistical
significance. The relationship between changes in SDLP
and subjective assessments is shown in Figs. 1, 2,a n d3.
The overall analyses revealed significant correlations for
perceived driving quality (r=−0.498, p<0.0001), mental
effort to perform the test (r=0.408, p<0.0001), and
alertness taken before driving (r=− 0.115, p<0.017). Thus,
the predictive validity (R
2) of perceived driving quality
(24.8%) and mental effort (16.6%) was moderate to low, but
importantly, predictive validity of alertness before driving
(1.3%) was virtually absent. Thus, the only measure taken
before the actual drive, and therefore the only measure of
predicting rather than evaluating performance, showed the
lowest predictive validity. Overall results and those for
individual drugs are summarized in Table 3.
It is evident from Table 3 (data from individual drug
treatment analyses) that the correlation between SDLP
differences from placebo and subjective assessments is
highly variable between studies with no clear relation with
drugs, doses, or times of drug administration relative to
time of driving. It is important to recognize that these are
the data that are gathered for individual research projects.
Discussion
The analyses show that subjective assessments, especially
predictive ones, do not robustly relate to actual driving
performance either in terms of judgments about alertness
before the drive or ratings of performance after the drive. This
is especially true when the data are analyzed study by study.
The present findings have important clinical and publichealth
Fig. 1 Relationship between
changes from placebo of SDLP
and subjective driving ability
Fig. 2 Relationship between
changes from placebo of SDLP
and mental effort to perform the
driving test
778 Psychopharmacology (2012) 219:775–781implications as it is typically the patient’sr e s p o n s i b i l i t yt o
make a decision whether or not to initiate a drive and whether
to continue driving after they have experienced how they
drive under the medication. In fact, the direction to patients to
experience the drug several times before they undertake
operating machinery presupposes that patients will accurately
assesstheirperformanceundertheinfluenceofthemedication
and thereby make informed decisions.
Whenever participants drive a vehicle, they make a
subjective estimate of how they are feeling at that time and
location in comparison to their normal driving state.
Therefore, the rationale for the statistical analyses was to
use difference scores from placebo. This approach was
chosen because it provides information if drivers can
adequately assess changes from their normal driving
performance. Where there are significant differences from
placebo for SDLP (see Table 3), these are associated with
increases in mental effort (except for alcohol) and decreases
in perceived driving quality. Therefore, participants were
retrospectively consistently aware of impairment. These
findings were much less consistent for differences in SDLP
and alertness assessed before driving. For example, while
both drugs significantly impair driving, alertness before the
test was significantly decreased for zolpidem, but increased
for diphenhydramine (day 4). The analyses on difference
scores from placebo revealed statistically significant corre-
lations for perceived driving quality, mental effort to
perform the test, and alertness before driving, but the
percentage of predictive validity towards changes in SDLP
was low. Correlations between absolute values of SDLP
and subjective assessments of driving ability are not very
informative. The primary reason for this is that SDLP
Fig. 3 Relationship between
changes from placebo of SDLP
and alertness before the driving
test
Table 3 Correlation between SDLP differences from placebo (centimeters) and perceived driving quality, mental effort to perform the test, and
alertness before driving
Treatment N ΔSDLP Mental effort Driving quality Alertness
Zolpidem (20 mg) 30 +10.41*** +0.488** −0.809 ** −0.480 **
Alprazolam (1 mg) 18 +9.62*** +0.364 −0.205 +0.366
Zolpidem (10 mg) 30 +3.35*** +0.512 ** −0.592 ** −0.653 **
Diphenhydramine (50 mg, day 1) 48 +2.74*** +0.160 −0.438 ** +0.169
Oxycodone/paracetamol (10/650 mg) 18 +1.87 +0.455 −0.476 * −0.189
Diphenhydramine (50 mg, day 4) 48 +1.56*** +0.268 −0.526** +0.327*
Alcohol (BAC=0.05%) 29 +1.03*** −0.002 −0.153 +0.148
Bromfenac (50 mg) 18 +0.51 +0.308 −0.334 +0.070
Levocetirizine (5 mg, day 4) 48 +0.46 +0.378 ** −0.319 * +0.126
Zaleplon (10 mg) 30 −0.45 +0.381 * −0.305 −0.278
Zaleplon (20 mg) 30 +0.43 +0.447 * −0.515 ** −0.409 *
Levocetirizine (5 mg, day 1) 48 +0.22 +0.361 * −0.347 * −0.068
Oxycodone/paracetamol (5/325 mg) 18 −0.65 +0.514 * −0.513 * +0.251
Bromfenac (25 mg) 18 −0.66 +0.562 * −0.541 * +0.608 **
Overall 431 +2.03 0.408 ** −0.498 ** −0.115 *
*p<0.05 and **p<0.01, significance of the Pearson’s r correlation with SDLP; ***p<0.05, SDLP differs significantly from placebo
Psychopharmacology (2012) 219:775–781 779values differ greatly between participants (Verster and Roth
2011). Hence, one subject may regard an SDLP of 15 cm as
normal, whereas another participant regards an SDLP value
of 25 cm as normal. As placebo (absolute) values between
participants are so variable, they cannot be used to provide
a quantitative comparison.
These data show that participants are not always able to
accurately judge changes in their driving performance after
administration of CNS drugs. The data also show that
mental effort to conduct the test is a poor indicator of the
driving impairment they experienced. Of greater concern is
that the level of alertness before driving does not predict
driving performance. Although the correlation was signif-
icant (at least in part due to the large number of subjects as
well as the number of different drug treatments), the
predictive validity was only 1.3%. The poor correlation
between perceived level of alertness and actual perfor-
mance is caused by the fact that the awareness of reduced
alertness differs between CNS drugs (See Table 3). For
example, whereas driving was severely impaired after both
administration of zolpidem (20 mg) and alprazolam (1 mg),
alertness correlated significantly with SDLP only after
zolpidem, but not after alprazolam. Also, perceived driving
quality did not correlate significantly with driving impair-
ment caused by alprazolam. In contrast, after administration
of zolpidem even at a high dose (20 mg), drivers were fully
aware of their performance impairment. These findings
illustrate the importance of obtaining these subjective
assessments to compliment the objective measurements of
driving performance. It provides useful information wheth-
er drivers are aware of driving impairment, or if participants
have to invest significantly more effort to prevent driving
impairment.
A limitation of this study is that we did not directly ask
participants before the start of the driving test to what
extent they anticipated their driving would be impaired.
Nevertheless, it can be assumed that many people make this
judgment based on the level of alertness they experience.
Of interest for future research is to conduct assessments of
subjective driving quality during the driving test. The
objective and subjective measurements would then be truly
concurrent assessments. Making these assessments several
times during the driving test would also enable showing
whether the subjective assessments are in line with the
objective performance decrement generally seen during the
driving test (Verster and Roth 2011).
The results of the current analyses are consistent with the
literature on sleep deprivation that also shows a lack of a
relation between perceived performance impairment and
actual performance impairment (Herscovitch and
Broughton 1981; Van Dongen and Belenky 2009). This
has important clinically relevant implications. First, people
should not rely solely on their perceived alertness when
deciding whether or not it is safe to drive a car after using
CNS drugs. The poor correlation between subjective and
objective driving ability shows that the general advice that
“patients should listen to their body, and not drive if they
feel their driving is impaired” should not be relied on
because patients may not be aware of their driving
impairment. Physicians should therefore urge patients to
follow-up labeling instructions regarding drug effects on
driving. In addition, patients should be informed that they
may not be aware of impaired driving, or do not experience
reduced alertness while at the same time their performance
may be significantly impaired. Physicians should take a
more active role in educating patients about the possible
risks of drug use in combination with daily activities such
as driving. This proactive approach by physicians is
important because many patients do not read nor follow-
up instructions of prescription drug labeling (Veldhuijzen et
al. 2006). Although several CNS drugs can impair driving,
often alternative pharmacological treatments are available
that do not affect driving ability or more typically have a
lesser effect on driving. When a patient needs to drive a car
regularly, physiciansshouldincorporatethe dataontheeffects
of the drug on driving performance into their overall selection
of the most appropriate medication for this patient.
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